RESEARCH ARTICLE

Monitoring disease activity and severity in lupus [version 1; peer review: 2 approved with reservations]

Abidullah Khan , Iqbal Haider, Maimoona Ayub, Salman Khan

Department of Medicine, Khyber Teaching Hospital, Peshawar, 25000, Pakistan

V1 First published: 10 Feb 2017, 6:126
<https://doi.org/10.12688/f1000research.10763.1>
 Second version: 24 Feb 2017, 6:126
<https://doi.org/10.12688/f1000research.10763.2>
 Latest published: 16 Mar 2017, 6:126
<https://doi.org/10.12688/f1000research.10763.3>

Abstract

Background: Systemic lupus erythematosus (SLE) is a relatively uncommon disease of young females in Pakistan. Usually, it has a relapsing-remitting course with variable severity and disease activity. Amongst the different clinical and laboratory parameters used to monitor disease activity in lupus, mean platelet volume (MPV) is a novel biomarker. Although MPV has been studied in other rheumatological conditions like rheumatoid arthritis, its role in adult SLE needs to be defined, especially in Pakistan. **Methods:** The aim of this study was to evaluate the role of MPV as a biomarker of disease activity in SLE. This study included 25 patients with active SLE, and another 25 participants with stable, inactive lupus. MPV was measured in each group and compared using SPSS version 16. MPV was also correlated with SLE disease activity index (SLEDAI) and erythrocyte sedimentation rate (ESR). Independent sample t-test and Pearson's correlation tests were applied. Sensitivity and specificity of MPV were checked through ROC analysis. **Results:** The MPV of patients with active SLE (n=25, mean [M]=7.12, SD=1.01) was numerically lower than those in the inactive-SLE group (n=25, M= 10.12, SD=0.97), and this was statistically significant ($P<0.001$). MPV had an inverse relationship with both ESR ($r=-0.93$, $P<0.001$) and SLEDAI ($r=-0.94$, $P<0.001$). However, there was a strong positive correlation between ESR and SLEDAI ($r=0.95$, $P<0.001$). For MPV, a cutoff value of less than 8.5fl had a sensitivity of 92% and a specificity of 100% ($P<0.001$). **Conclusions:** Higher disease activity in SLE is associated with a correspondingly low MPV.

Keywords

systemic lupus erythematosus, blood platelets, platelets aggregation

Open Peer Review

Approval Status

	1	2
version 3		
(revision)		
16 Mar 2017	view	
version 2		
(revision)		
24 Feb 2017	view	view
version 1		
10 Feb 2017	view	view

1. **Guillermo Delgado-García** , National Institute of Neurology and Neurosurgery, Mexico City, Mexico

2. **Alina Dima** , Aarhus University Hospital, Aarhus, Denmark

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Lupus nephritis**
and **neuropsychiatric lupus** collection.

Corresponding author: Abidullah Khan (dr.abidullahk@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Khan A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Khan A, Haider I, Ayub M and Khan S. **Monitoring disease activity and severity in lupus [version 1; peer review: 2 approved with reservations]** F1000Research 2017, 6:126 <https://doi.org/10.12688/f1000research.10763.1>

First published: 10 Feb 2017, 6:126 <https://doi.org/10.12688/f1000research.10763.1>

Abbreviations

MPV: Mean Platelet Volume, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLE: Systemic Lupus Erythematosus, ESR: Erythrocyte Sedimentation Rate, CRP: C-reactive Protein, ACR: American College of Rheumatology.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that can affect any organ system of the body. It has an annual incidence of 5 per 100,000 of the general population¹. There are racial and ethnic variations, with higher rates reported in Black and Hispanic peoples². Usually, this disease with protean manifestations has a remitting relapsing course; however, it has a tendency to vary from acutely progressive to chronic indolent forms^{1,2}.

The clinical manifestations of SLE range from constitutional symptoms, such as fever, sweats, weight loss, joint pains and skin rashes (including the classic butterfly rash), to more serious features, including the involvement of the central nervous system and kidneys. However, to make a clinical diagnosis of SLE, simultaneous or sequential presence of 4 out of a total of 11 criteria, proposed by the American College of Rheumatology (ACR), must be present^{3,4}.

Considering the remitting relapsing nature of most cases of SLE, it is important to have a biomarker to monitor its disease activity. Although, the most effective and reliable tool to measure SLE disease activity is still open to debate, there are fortunately many validated measures, including the Systemic Lupus Activity Measure, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Lupus Activity Index, European Consensus Lupus Activity Measurement, and British Isles Lupus Activity Group⁵. These tools have been found to be beneficial in day to day practice^{6,7}.

Notable issues, apart from some other technical limitations, with the aforementioned severity assessment indices are that these validated instruments are confusing, lengthy and time consuming. However, very recently, mean platelet volume (MPV) has been shown to be a very good and easily accessible marker of disease activity in lupus⁸⁻¹⁰. Although MPV has been studied well as a simple but reliable inflammatory biomarker in several diseases, such as rheumatoid arthritis, scleroderma, rheumatic fever, ankylosing spondylitis and even chronic obstructive pulmonary disease, there is still a relative scarcity of its role as a disease severity indicator in lupus¹¹⁻¹⁵. Therefore, we performed the present study to find out whether MPV does or does not correlate with SLEDAI and whether it can be used a predictor of lupus severity and activity.

Methods

Patient characteristics

This cross-sectional study was conducted in the Department of Medicine of Khyber Teaching Hospital (KTH; Peshawar, Pakistan) between January 2015 and July 2016. Medical records, intranet of our hospital and referrals by the general practitioners were the sources of recruitment. Patient information sheet, letters and direct contact by the investigators, who were directly involved in the

provision of healthcare to potential subjects, were the chief methods of recruitment. This study was approved by the Ethics Review Committee of the hospital and a written informed consent was obtained from every participant (approval number, KTH/2015/Med-A/86C). The patient sample was collected using a consecutive-random sampling technique. Nevertheless, as is true of cross-sectional studies, confounding and sample selection bias may be limitations to the generalization of our results.

Patients from both genders in the age range of 18–70 years, and those with both either newly diagnosed or pre-existing SLE were included in the study. In order to avoid bias, only those patients with a normal platelet count were included. This is because; MPV is influenced by the number of platelets in circulation. The ACR criteria for the diagnosis of SLE was used as a diagnostic tool.

Individuals who had history of smoking, acute or chronic infectious diseases, hemoglobin >16.5 g/dl, thrombocytopenia (platelets <150,000/mm³), hypertension, angina pectoris, myocardial infarction, diabetes mellitus, hypo- or hyperthyroidism, anti-phospholipid syndrome, recurrent miscarriage, amyloidosis, thrombosis and acute or chronic renal failure were excluded from the study. Patients who had either clinical, biochemical or serological evidence of an autoimmune disorder other than SLE, such as rheumatoid arthritis, Sjogren's syndrome or scleroderma, were also excluded from the study.

The sample size was calculated by using 5% margin of error and 95% CI on the WHO's formula for determination of sample size in health studies (<http://www.who.int/chp/steps/resources/sampling/en/>). A total of 64 patients were assessed initially. However, only 50 of them satisfied the inclusion and exclusion criteria. The 50 participants recruited were divided into two equal groups, 25 subjects each in the active-SLE and the inactive-SLE groups, as detailed below.

SLEDAI

The participants were divided into two groups, active and inactive SLE groups. The division of the patients into two groups was based on their final score from using the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000)¹⁶. Those who scored 5 or higher were classified as active-SLE, while those with a final score of less than 5 were regarded as patients with inactive-SLE. Patients with active-SLE, fulfilling the inclusion criteria (SLEDAI-2000), were admitted to any one of the five medical wards of KTH for further workup and treatment. However, those with stable inactive disease were recruited in the study from the Outpatient Department of KTH.

Measurement of MPV

A total of 5ml of venous blood was taken in an EDTA tube from every participant for the measurement of complete blood count, including hemoglobin, white blood cells, platelets, MPV, and erythrocyte sedimentation rate (ESR). All the blood samples were analyzed within less than one hour after sampling. The complete blood count, including all the hematological parameters, was performed using the same hematology analyzer, Medonic. The tests were performed and read by the same laboratory technician of KTH.

Data analysis

All the data was entered on a structured questionnaire specifically designed for this study ([Supplementary File 1](#)). Data was transferred to and analyzed using SPSS version 16. Means and standard deviations were determined for quantitative variables. Independent sample t-test was run to compare means of MPV between the two groups. ROC analysis was performed to estimate cutoff values for sensitivity and specificity of MPV. Finally, Pearson's correlation test was used to assess any association between MPV, ESR and SLEDAI. *P* value of less than 0.05 was considered as significant.

Results

Of the 50 participants, 84% were female and 16% were male. There were 4 males and 21 females in each of the active- and inactive-SLE groups, respectively. Other demographic details are shown below ([Figure 1](#)). The overall mean age of all the participants was 27.94 ± 2.52 years. The mean age of the patients in the active-SLE group ($M=27.84$, $SD=2.06$) was comparable to the inactive-SLE group ($M=29.60$, $SD=2.38$). The clinical features of patients with active- and inactive-SLE are shown in [Table 1](#) and [Table 2](#), respectively. In the active-SLE group, 11 (44%) patients had evidence of clinically significant proteinuria; details of the histological sub-type of lupus nephritis are given in [Table 3](#).

The MPV of patients with active-SLE ($n=25$, $M=7.12$, $SD=1.01$) was numerically lower than those in the inactive-SLE group ($n=25$, $M=10.12$, $SD=0.97$). An independent sample t-test was run to compare the means of the two groups. The assumption of normality was tested by Kolmogorov-Smirnov test and was found tenable ($P > 0.05$). Moreover, similar results were obtained

on Skewness and Kurosis testing (skewness=0.01, kurtosis= -1.06). The assumption of homogeneity of variances was tested using Levene's test and was found tenable ($F(48) = 0.23$; $P=0.63$). The results of the independent t-test showed a statistically significant difference between the mean values of MPV of the two groups ($t(48) = 10.69$; $P < 0.001$; Cohen's $D=3.02$). The 95% Confidence Interval (CI) was -3.56 to -2.44. Receiver operator characteristic (ROC) curve was used to check the specificity and sensitivity of MPV ([Figure 2](#)). The ROC curve had an area under the curve of 0.98. At a value of 8.5fl for MPV, the sensitivity and specificity were 92% and 100%, respectively, ($P < 0.001$; 95%CI -0.96 to +1.01). At a cutoff value of 8.5fl, MPV has a maximum sensitivity and specificity. Therefore, we recommend that, at an MPV value of <8.5 fl, the probability of SLE increases remarkably.

The SLEDAI scores between the two groups, active-SLE ($M=16.36$, $SD=4.48$) and inactive-SLE ($M=3$, $SD=0.82$), varied at a statistically significant level of $P < 0.001$. The ESR was higher in patients with active SLE ($M=49.52$, $SD=12.93$) than those with stable disease ($M=13.76$, $SD=1.72$) ($P < 0.001$). The details of the different hematological parameters are given in [Table 4](#).

Pearson's correlation test was run to assess any relationship between MPV, SLEDAI and ESR in the active-SLE group. The results showed a statistically significant, negative correlation of MPV with both ESR ($r = -0.93$, $P < 0.001$) and SLEDAI ($r = -0.94$, $P < 0.001$). Moreover, there was a strong positive correlation between ESR and SLEDAI ($r = 0.95$, $P < 0.001$). Hence, it can be argued that increased disease activity of SLE is associated with both a higher ESR and SLEDAI score, and a correspondingly low MPV ($P < 0.001$).

Patients characteristics

Figure 1. Demographic details of patients in each group ($n=25$).

Table 1. Overview of clinical characteristics of patients with active-SLE.

CLINICAL FEATURES	PATIENTS, N (%)
Polyarthritis	22 (88)
Butterfly rash	16 (64)
Photosensitivity	20 (80)
Patchy alopecia	15 (60)
Pleurisy	14 (56)
Pericarditis	2 (8)
Neuropsychiatric problems	13 (52)
Oral ulcers	20 (80)
Proteinuria (>0.5gm/day)	11 (44)
Anti-dsDNA antibodies	24 (96)
Antinuclear factor	23 (92)

Table 2. Overview of the clinical characteristics of patients with inactive-SLE.

CLINICAL FEATURES	PATIENTS, N (%)
Non-specific aches and pains	17 (67)
Malaise	14 (54)
Dyspepsia	13 (53)
Anorexia	10 (40)
Photosensitivity	6 (23)
Non-scarring alopecia	5 (19)

Table 3. Overview of the renal histology in 11 patients with active-SLE and proteinuria.

Histological type of lupus nephritis	Patients, N (%)
Focal proliferative glomerulonephritis	3 (27)
Diffuse proliferative glomerulonephritis	7 (64)
Membranous glomerulonephritis	1 (9)

Dataset 1. Raw data of disease severity indicators in lupus

<http://dx.doi.org/10.5255/f1000research.10763.d151064>

This file contains data regarding disease severity indicators and demographics of patients with SLE. This coded data was stored on SPSS version 16. Group: 1, active-SLE; 2, inactive-SLE. Gender: 1, male; 2, female. SLEDAI, systemic lupus erythematosus disease activity index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cell (thousand/mm³); Hb, hemoglobin (gm/dl); platelets, platelet count × 10³.

Discussion

SLE, which is more common in Black women, has a female to male ratio of approximately 9:1¹¹. Our study group comprised of 84% female and 16% male population. Furthermore, most of the participants in our study were in the third decade of life. Participants with active-SLE were younger than those with the stable form of the disease. These findings are comparable to international statistics^{17,18}. We observed that MPV was significantly lower in patients with active lupus than those without a flare. Similarly, we found that, MPV had a tendency to be lower with a correspondingly higher ESR in individuals with actively flaring SLE and vice versa. Moreover, we observed that SLEDAI was as effective as both ESR and MPV, as an indicator of disease activity in patients with SLE.

ROC Curve **Figure 2. ROC analysis for sensitivity and specificity of mean platelet volume.****Table 4. Comparison of different test variables between the two study groups. SLEDAI, Systemic Lupus Erythematosus Disease Activity; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cells; Hb, hemoglobin.**

Variable	Active-SLE		Inactive-SLE		P value
	Mean	SD	Mean	SD	
SLEDAI	16.36	4.48	3.00	0.82	< 0.001
MPV (fl)	7.12	1.01	10.12	0.97	< 0.001
ESR (1 st hour)	49.52	12.93	13.76	1.72	< 0.001
Platelets×10 ³ /mm ³	259.72	1.10	259.68	1.03	0.89
WBC/mm ³	5422.00	396.68	5896.00	79.53	< 0.001
Hb (gm/dl)	11.64	1.04	13.56	0.87	< 0.001

Gasparian *et al.* concluded that high MPV correlated with a variety of diseases, like cardio- and cerebrovascular disorders, venous and arterial thrombosis and low-grade inflammatory conditions¹⁹. However, it was observed that, high intensity inflammatory disorders, such as active rheumatoid arthritis or relapses of familial Mediterranean fever, had low values of MPV, which could be reverted with anti-inflammatory medications^{20,22}. Although we did not check the effect of anti-inflammatory medications, like corticosteroids, on MPV, we observed a strong inverse relationship of MPV with lupus severity and activity. Therefore, we recommend MPV as a global marker of disease activity in patients with SLE.

Apart from MPV, ESR has traditionally been used as a marker of disease severity in patients with inflammatory conditions, and SLE, specifically²³. Similarly, C-reactive protein (CRP) has been studied, but not been found to be a marker of disease activity in lupus²⁴. It is worth mentioning that, usually, there is a discordance between ESR and CRP in actively diseased SLE patients²⁵. In our study, ESR correlated positively with both MPV and SLEDAI, which is consistent with these previous results.

Why is MPV low in active SLE? The answer cannot be clearly stated. However, previous studies have shown that, in active inflammatory conditions, especially rheumatoid arthritis and SLE, large and activated platelets are consumed preferentially at the site of inflammation, leaving small platelets behind^{20–21}. This may also explain lower MPV values in actively flaring SLE patients in our study group.

Considering active-SLE as a state of severe inflammation, those with active disease in our study were treated with 1g daily dose of methylprednisolone for three days, followed by a maintenance dose of 1mg/Kg oral prednisolone for another 4–6 weeks. Although, all participants with active lupus achieved dramatic symptomatic and clinically obvious improvement, MPV was not studied after the completion of steroid therapy. However, in other studies, where pre-treatment MPV was compared with post-treatment MPV, it was observed that, after successful treatment with anti-inflammatory medications, MPV reverted back to normal^{21–26}. Considering this data, we would advocate future studies focusing on comparing pre- and post-treatment MPV in patients treated with corticosteroids for acute flare of SLE.

It is noteworthy that; although, most of the studies found an inverse relationship between active-SLE and MPV in adults, a positive association was observed between MPV and disease activity in juvenile lupus erythematosus¹⁰. This finding of positive correlation between MPV and disease activity in juvenile lupus is in sharp contrast to the results of our and similar previous studies^{8,9}.

Notably, the results of this study were in accordance with the expectations of authors. Moreover, considering recent research studies showing a link between low MPV and disease activity in SLE patients, our study will add further evidence. However a limitation to the conduct and results of this study was a small sample size. This is because, SLE is not very common in Pakistan. Therefore, in order to highlight the actual role of MPV as a biomarker of lupus severity, we recommend that, cohort studies should be done in future, both in Pakistan and abroad.

Conclusions

MPV is an excellent biomarker to monitor disease activity in SLE, as higher disease activity will reduce MPV and vice versa. Moreover, MPV has an inverse relationship with both ESR and SLEDAI. At a cutoff value of less than 8.5fl, MPV has an excellent sensitivity and specificity.

Ethics approval and consent

This study was approved by Ethics Review Committee of Khyber Teaching Hospital, Peshawar, Pakistan (approval number, KTH/2015/Med-A/86C). Informed written consent was obtained from every participant.

Data availability

Dataset 1: Raw data of disease severity indicators in lupus.

This file contains data regarding disease severity indicators and demographics of patients with SLE. This coded data was stored on SPSS version 16. Group: 1, active-SLE; 2, inactive-SLE. Gender: 1, male; 2, female. SLEDAI, systemic lupus erythematosus disease activity index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cell (thousand/mm³); Hb, hemoglobin (gm/dl); platelets, platelet count $\times 10^3$. doi, [10.5256/f1000research.10763.d151064](https://doi.org/10.5256/f1000research.10763.d151064)²⁷

Author contributions

AK, IH, MA and SK conceived the idea and formulated the study design. All the authors contributed to the drafting of this manuscript. All the authors read the manuscript before approval and submission.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Supplementary material

Supplementary File 1: Lupus severity and disease activity questionnaire. This questionnaire was used to gather data from the participants. SLEDAI, systemic lupus erythematosus disease activity index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; WBC, white blood cell (thousand/mm³); active SLE, SLEDAI >5 points; inactive SLE, SLEDAI <5 points.

[Click here to access the data.](#)

References

- Magro-Checa C, Zirkzee EJ, Huizinga TW, *et al.*: **Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.** *Drugs*. 2016; **76**(4): 459–483.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Crampton SP, Morawski PA, Bolland S: **Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus.** *Dis Model Mech*. 2014; **7**(9): 1033–1046.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Arriens C, Mohan C: **Systemic lupus erythematosus diagnostics in the “omics” era.** *Int J Clin Rheumatol*. 2013; **8**(6): 671–687.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bartels CM, Buhr KA, Goldberg JW, *et al.*: **Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort.** *J Rheumatol*. 2014; **41**(4): 680–687.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rai SK, Yazdany J, Fortin PR, *et al.*: **Approaches for estimating minimal clinically important differences in systemic lupus erythematosus.** *Arthritis Res Ther*. 2015; **17**(1): 143.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- http://www.medscape.com/viewarticle/848817_2
- Mikdashi J, Nived O: **Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.** *Arthritis Res Ther*. 2015; **17**(1): 183.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rupa-Matysek J, Gil L, Wojtasińska E, *et al.*: **The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome.** *Rheumatol Int*. 2014; **34**(11): 1599–1605.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Safak S, Uslu AU, Serdal K, *et al.*: **Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis.** *Afr Health Sci*. 2014; **14**(4): 919–924.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yavuz S, Ece A: **Mean platelet volume as an indicator of disease activity in juvenile SLE.** *Clin Rheumatol*. 2014; **33**(5): 637–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Şahin A, Yetişgin A, Şahin M, *et al.*: **Can Mean Platelet Volume be a Surrogate Marker of Inflammation in Rheumatic Diseases?** *West Indian Med J*. 2016; **65**(1): 165–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yolbas S, Yildirim A, Gozel N, *et al.*: **Hematological Indices May Be Useful in the Diagnosis of Systemic Lupus Erythematosus and in Determining Disease Activity in Behçet's Disease.** *Med Princ Pract*. 2016; **25**(6): 510–516.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhang M, Li Y, Zhang J, *et al.*: **Mean platelet volume is elevated in exacerbated and convalescent COPD patients.** *Clin Chim Acta*. 2015; **451**(Pt B): 227–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Balbaloglu O, Korkmaz M, Yolcu S, *et al.*: **Evaluation of mean platelet volume (MPV) levels in patients with synovitis associated with knee osteoarthritis.** *Platelets*. 2014; **25**(2): 81–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ulasli SS, Ozyurek BA, Yilmaz EB, *et al.*: **Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease.** *Pol Arch Med Wewn*. 2012; **122**(6): 284–90.
[PubMed Abstract](#)
- Gladman DD, Ibañez D, Urowitz MB: **Systemic lupus erythematosus disease activity index 2000.** *J Rheumatol*. 2002; **29**(2): 288–91.
[PubMed Abstract](#)
- Helmick CG, Felson DT, Lawrence RC, *et al.*: **Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.** *Arthritis Rheum*. 2008; **58**(1): 15–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ambrose N, Morgan TA, Galloway J, *et al.*: **Differences in disease phenotype and severity in SLE across age groups.** *Lupus*. 2016; **25**(14): 1542–1550.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gasparyan AY, Ayvazyan L, Mikhailidis DP, *et al.*: **Mean platelet volume: a link between thrombosis and inflammation?** *Curr Pharm Des*. 2011; **17**(1): 47–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Aksu H, Ozer O, Unal H, *et al.*: **Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes.** *Blood Coagul Fibrinolysis*. 2009; **20**(80): 686–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, *et al.*: **Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF- α therapy.** *Rheumatol Int*. 2010; **30**(8): 1125–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kim DA, Kim TY: **Controversies over the interpretation of changes of mean platelet volume in rheumatoid arthritis.** *Platelets*. 2011; **22**(1): 79–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dima A, Opris D, Jurcut C, *et al.*: **Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus?** *Lupus*. 2016; **25**(11): 1173–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gaitonde S, Samols D, Kushner I: **C-reactive protein and systemic lupus erythematosus.** *Arthritis Rheum*. 2008; **59**(12): 1814–1820.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pisetsky DS: **Anti-DNA and autoantibodies.** *Curr Opin Rheumatol*. 2000; **12**(5): 364–368.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Vakili M, Ziaee V, Moradinejad MH, *et al.*: **Changes of Platelet Indices in Juvenile Idiopathic Arthritis in Acute Phase and After Two Months Treatment.** *Iran J Pediatr*. 2016; **26**(3): e5006.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Khan A, Haider I, Ayub M, *et al.*: **Dataset 1 in: Monitoring disease activity and severity in lupus.** *F1000Research*. 2017.
[Data Source](#)

Open Peer Review

Current Peer Review Status: ? ?

Version 1

Reviewer Report 17 February 2017

<https://doi.org/10.5256/f1000research.11605.r20320>

© 2017 Dima A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alina Dima

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

- Title:** I don't find the term "monitoring" appropriate as it is presented a cross-sectional study with only one MPV determination and I so think that the use of assessment or determination could be tried.
Also the term MPV (as possible marker of SLE disease activity) should be included in title.
- Abstract:** First two phrases of the abstract are too general, not directly related to this article subject. I think that for the background the idea MPV – activity – Inflammation – SLE is enough.
In the method we understand that 25 patients with active vs. 25 inactive were chosen ... it should be clear noted; e.g. cross-sectional, prospective, successively inclusion and then how the two subgroups were defined.
I don't think that the details of statistic should appear in the abstract - methods, maybe a more detailed conclusion.
- Introduction:** As for the abstract, I find the first two paragraphs are too general, not directly related to the article topic.
For the classification criteria, instead of classification criteria up-dated ACR 1997 (that should be cited properly) I would propose the use of SLICC 2012 or both criteria sets; but anyway, the diagnosis would be the same as the last criteria set is more sensitive.
- Methods/ Results:** There are many exclusion criteria presented, maybe there could be some words in introduction or discussion about these factors influence on MPV (as it was discussed for thrombocytopenia) and reasons of exclusion.
I understand from methods that it was a cross-sectional study with random, consecutive inclusion and then the lot was split in two groups according to SLE disease activity (assessed by SLEDAI).
How was the SLEDAI cut-off of 5 points determined? This cut-off appears in previous published research, it is the mean value (as I understand all variables turned out to be parametric), or the group was split in two groups of similar patients number?

And then, the bivariate correlations were realized only in the group with active SLE, so the results are applicable only in this subgroup of patients.

I would propose a logistic regression for the entire lot (50 patients), with MPV, ESR (and adjusted for age and gender) as predictors for high SLEDAI.

However, the degree of correlation obtained is very high and so it sustains the research conclusion.

5. **Discussion:** the phrase "SLEDAI was as effective as both ESR and MPV" should be written differently (MPV was correlated with/ is an effective marker of ...) as the research is about MPV, disease activity was assessed by SLEDAI and ESR was noted as parameter known to correlates with disease activity.

In the third paragraph, I don't find a relation between the discussion on CRP and the same paragraph last phrase. Of course, data on ESR usefulness as marker of SLE disease activity should be discussed in order to understand why SLEDAI and ESR as standard. And maybe also data on ESR and MPV in lupus or other diseases, if there are.

6. **Conclusion:** I think that the first phrase of conclusion should be reformulated. The term "monitor" I already discussed; "higher disease will reduce MPV" could be more specific; and "vice versa" I'm not sure that this can be concluded as the study does not discuss distinctly the relation between higher MPV with lower activity in the subgroup of inactive lupus patients (of course, it looks logical).

I think also that the present last phrase of conclusion should be ended "sensitivity and specificity for ..." and in active SLE, without APS ...

Competing Interests: An article in which I am co-author was cited in the present research. No financial competing interests.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 21 Feb 2017

Abidullah Khan, Khyber Teaching Hospital, Peshawar, Pakistan

We are really grateful to Alina Dima for her invaluable comments on our article. Please find below a point-wise response to the comments.

1. **Title:** "I don't find the term "monitoring" appropriate as it is presented a cross-sectional study with only one MPV determination and I so think that the use of assessment or determination could be tried. Also the term MPV (as possible marker of SLE disease activity) should be included in title."

Reply: *This suggestion has been incorporated.*

2. **Abstract:** "First two phrases of the abstract are too general, not directly related to this article subject. I think that for the background the idea MPV – activity – Inflammation – SLE is enough. In the method we understand that 25 patients with active vs. 25 inactive were chosen ... it should be clear noted; e.g. cross-sectional,

prospective, successively inclusion and then how the two subgroups were defined. I don't think that the details of statistic should appear in the abstract - methods, maybe a more detailed conclusion."

Reply: Abstract has been re-phrased as suggested. However, we believe that, the statistics should appear in the abstract, as they give an overall idea to the researcher of what we did and what s/he may expect to find in the results?

3. **Introduction:** As for the abstract, I find the first two paragraphs are too general, not directly related to the article topic. For the classification criteria, instead of classification criteria up-dated ACR 1997 (that should be cited properly) I would propose the use of SLICC 2012 or both criteria sets; but anyway, the diagnosis would be the same as the last criteria set is more sensitive.

Reply: We have intentionally left the first two paragraphs as general looking. This is for the purpose of education of the young researchers and to give an impression as, how does SLE behave normally ?

4. **Methods/ Results:** There are many exclusion criteria presented, maybe there could be some words in introduction or discussion about these factors influence on MPV (as it was discussed for thrombocytopenia) and reasons of exclusion.

Reply: Sentence has now been added regarding the influence of the set exclusion criteria on MPV and the study results.

I understand from methods that it was a cross-sectional study with random, consecutive inclusion and then the lot was split in two groups according to SLE disease activity (assessed by SLEDAI). How was the SLEDAI cut-off of 5 points determined? This cut-off appears in previous published research, it is the mean value (as I understand all variables turned out to be parametric), or the group was split in two groups of similar patients number? And then, the bivariate correlations were realized only in the group with active SLE, so the results are applicable only in this subgroup of patients. I would propose a logistic regression for the entire lot (50 patients), with MPV, ESR (and adjusted for age and gender) as predictors for high SLEDAI. However, the degree of correlation obtained is very high and so it sustains the research conclusion.

Reply: The recommended changes have been made.

5. **Discussion:** the phrase "SLEDAI was as effective as both ESR and MPV" should be written differently (MPV was correlated with/ is an effective marker of ...) as the research is about MPV, disease activity was assessed by SLEDAI and ESR was noted as parameter known to correlates with disease activity. In the third paragraph, I don't find a relation between the discussion on CRP and the same paragraph last phrase. Of course, data on ESR usefulness as marker of SLE disease activity should be discussed in order to understand why SLEDAI and ESR as standard. And maybe also data on ESR and MPV in lupus or other diseases, if there are.

Reply: Discussion has been modified at points suggested by the respectable reviewer.

6. **Conclusion:** I think that the first phrase of conclusion should be reformulated. The

term “monitor” I already discussed; “higher disease will reduce MPV” could be more specific; and “vice versa” I’m not sure that this can be concluded as the study does not discuss distinctly the relation between higher MPV with lower activity in the subgroup of inactive lupus patients (of course, it looks logical). I think also that the present last phrase of conclusion should be ended “ sensitivity and specificity for ...” and in active SLE, without APS ...

Reply: The conclusion has been amended as recommended by the reviewer.

Moreover, the term 'vice versa' has been removed.

Thank you once more for your time and precious comments.

Competing Interests: No competing interests to declare.

Reviewer Report 13 February 2017

<https://doi.org/10.5256/f1000research.11605.r20146>

© 2017 Delgado-García G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Guillermo Delgado-García

National Institute of Neurology and Neurosurgery, Mexico City, Mexico

In this study, Khan et al explored the relationship between SLE disease activity and mean platelet volume (MPV). After reading this article, I have the following suggestions:

1. I think it would be good if the title were more specific (perhaps including such terms as “platelet size” or “platelet volume”).
2. Contrary to what is mentioned in the last paragraph of the Introduction, Rupa-Matysek et al.¹ did not include SLE patients in their study.
3. Our team also published an article on this topic², which is not mentioned in the Introduction, even when it appeared online before that of Yolbas et al³.
4. I would like to know if the sampling technique was consecutive or random. I'm inclined to think that consecutive (i.e., non-random) sampling was used.
5. I'm not sure if this STEPS Sample Size Calculator was the ideal one to estimate the sample size in the present study. I would like to know what other values were used in this calculation (level of confidence measure, MOE, baseline levels of the indicators, Deff, etc). I would also like to know which outcome was used to estimate the sample size. MPV? If so, why was not used a formula to determine the appropriate sample size for detecting a difference between the means of two samples?
6. One merit of this study when comparing it with others is that all the blood samples were

analyzed within less than one hour after sampling, since MPV increases over time in EDTA tubes.

7. I think that the bar chart is not ideal to display demographic information. Perhaps one table could be just enough.
8. I suggest the first two tables could be merged into one.
9. When calculating the correlations it is important to remember that the SLEDAI is an ordinal variable⁴.
10. In the discussion, when addressing the issue of pathophysiological mechanisms that could explain the decrease in MPV, two articles are cited. However, contrary to what is mentioned, neither of these articles deals with SLE patients.
11. It would be worthwhile to further discuss the findings of this study by comparing them more specifically with the other studies on this same topic.
12. There are some grammatical errors that would be worth correcting (e.g., an unnecessary semicolon in the second paragraph of the Methods).

References

1. Rupa-Matysek J, Gil L, Wojtasińska E, Ciepluch K, et al.: The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome. *Rheumatol Int.* 2014; **34** (11): 1599-605 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Delgado-García G, Galarza-Delgado DÁ, Colunga-Pedraza I, Borjas-Almaguer OD, et al.: Mean platelet volume is decreased in adults with active lupus disease. *Rev Bras Reumatol Engl Ed.* **56** (6): 504-508 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Yolbas S, Yildirim A, Gozel N, Uz B, et al.: Hematological Indices May Be Useful in the Diagnosis of Systemic Lupus Erythematosus and in Determining Disease Activity in Behçet's Disease. *Med Princ Pract.* 2016; **25** (6): 510-516 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Lew RA, Liang MH, Doros G: Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier. *Arthritis Res Ther.* 2015; **17**: 345 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: Financial competing interests: No competing interests were disclosed. Non-financial competing interests: Last year our team published an article on this same topic (*Rev Bras Reumatol.* 2016 Nov-Dec;56[6]:504-8).

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 21 Feb 2017

Abidullah Khan, Khyber Teaching Hospital, Peshawar, Pakistan

We thank Guillermo Delgado-Garcia from Mexico for reading our manuscript thoroughly and for pin-pointing various discrepancies. We have now corrected the shortcomings and we believe that, the changes made in the light of recommendation of our honorable reviewer will add a lot to the science of our article. Please find below, a point-by-point response to the reviewers comments;

1. The title of the article has been modified as suggested.

2. ***"Contrary to what is mentioned in the last paragraph of the Introduction, Rupa-Matysek et al. did not include SLE patients in their study".***

This has been rephrased. Thank you for identifying this.

3. The article published by your team is very informative and has now been referred to.

4. The sampling technique was consecutive. The sentence has been rewritten. Sorry for the mistake in version 1.

5. ***"I'm not sure if this STEPS Sample Size Calculator was the ideal one to estimate the sample size in the present study. I would like to know what other values were used in this calculation (level of confidence measure, MOE, baseline levels of the indicators, Deff, etc). I would also like to know which outcome was used to estimate the sample size. MPV? If so, why was not used a formula to determine the appropriate sample size for detecting a difference between the means of two samples?"***

We used both the methods. However, we mentioned the WHO sample size calculator only. All the missing info has now been added.

6. Thanks for your appreciation of the merits of our study.

7. Bar chart has now been replaced with a table as suggested.

8. ***"I suggest the first two tables could be merged into one".***

Merging the two tables will make the tables look lengthy and possibly confusing. Therefore, we believe that, illustration of the clinical features of the two groups in separate tables will be better read and understood.

9. ***"When calculating the correlations it is important to remember that the SLEDAI is an ordinal variable."***

We understand that SLEDAI is an ordinal variable. However, we used the final SLEDAI score rather than the overall conclusion (active/inactive) while running the correlation tests. As the SLEDAI score is continuous and in our case, was normally distributed, we believe running a correlation test was tenable.

10. ***"In the discussion, when addressing the issue of pathophysiological mechanisms that could explain the decrease in MPV, two articles are cited. However, contrary to what is mentioned, neither of these articles deals with SLE patients."***

This area has been rephrased. Thank you for pointing it out.

11. In our opinion, discussing the study further, will unnecessary lengthen the text of this article.

12. Every effort has been made to correct the English and grammar.
We thank you once more for your efforts.

Competing Interests: No competing interests to declare.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research